{"id":"W2557786287","doi":"10.1093/neuonc/now212.100","title":"ATIM-35. RESULTS OF THE PHASE IB KEYNOTE-028 MULTI-COHORT TRIAL OF PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT PD-L1-POSITIVE GLIOBLASTOMA MULTIFORME (GBM)","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Rash; Clinical endpoint; Cohort; Oncology; Surgery; Clinical trial; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002267616,0.0009840792,0.0008234176,0.0004184954,0.000396496,0.0008600127,0.0006028075,0.0008915505,0.0054242],"category_scores_gemma":[0.001450829,0.0003236151,0.001089833,0.000339472,0.0003873722,0.0006551367,0.0003756144,0.002021665,0.00104925],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007975245,"about_ca_system_score_gemma":0.00070143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007117823,"about_ca_topic_score_gemma":0.003574698,"domain_scores_codex":[0.9995492,0.0002171434,0.0000317848,0.00008262989,0.00004944357,0.00006972775],"domain_scores_gemma":[0.9995364,0.00007911024,0.0001254687,0.00003174222,0.00002805658,0.0001993598],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6163922,0.01612673,0.02492283,0.002515859,0.006078141,0.0004489108,0.0003482331,0.004391069,0.03535401,0.001377368,0.05543138,0.2366132],"study_design_scores_gemma":[0.6878206,0.169773,0.08617101,0.0002827073,0.004626492,0.0009523327,0.0001071998,0.002715203,0.005042223,0.0012691,0.0411598,0.00008027452],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9434376,0.01392698,0.001223257,0.002222292,0.0006106633,0.004000334,0.0181628,0.0004938703,0.01592218],"genre_scores_gemma":[0.9695222,0.003507432,0.002060094,0.002327508,0.0003299361,0.001784411,0.01566023,0.00005053928,0.004757546],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0054242,"threshold_uncertainty_score":0.01814574,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01553732485719488,"score_gpt":0.3030960722070924,"score_spread":0.2875587473498975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}